⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VKTX News
Viking Therapeutics, Inc
Form 8-K
sec.gov
VKTX
Non-Alcoholic Steatohepatitis (NASH/MASH) - Drug Pipeline Insight 2026 | 75+ Candidates Across 70+ Companies Drive Licensing and Investment Opportunities
globenewswire.com
NVO
VKTX
GSK
ALGS
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
prnewswire.com
VKTX
VKTK
Anti-Obesity Drugs Market Size, Share, Competitive Landscape, and Forecast to 2034 | GLP-1 Innovation Drives 14.0% CAGR Toward USD 148.6 Billion
globenewswire.com
LLY
AMGN
VKTX
TXMD
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
LLY
MRK
GSK
BMY
AZN
PFE
NVO
REGN
RDHL
AGIO
INCY
CRBP
BMRN
VKTX
RIGL
DTIL
CRDF
BIIB
ALKS
EXAS
CLDX
SRPT
TGTX
ALNY
CHKP
TAK
HHS
SERV
GILD
HRMY
IONS
BH
FORM
JNJ
GEN
ABBV
AMGN
CRSP
CHRD
ADPT
IMUX
ALGN
EXEL
VRTX
Form 8-K
sec.gov
VKTX
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
prnewswire.com
VKTX
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
prnewswire.com
VKTX
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
prnewswire.com
VKTX
Obesity Treatment Landscape 2026: Obesity Competitive Landscape and Clinical Trial Analysis 2026 Examines 200+ Companies and 200+ Drugs
globenewswire.com
LLY
NVO
NBIX
WVE
ALV
PFE
ABBV
AMGN
VKTX
ALNY